Subscribe to RSS
DOI: 10.1055/s-2006-942547
A Stereoselective Anti-Aldol Route to (3R,3aS,6aR)-Hexahydrofuro[2,3-b]furan-3-ol: A Key Ligand for a New Generation of HIV Protease Inhibitors
Publication History
Publication Date:
02 August 2006 (online)

Abstract
A stereoselective synthesis of (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-ol, an important high affinity P2-ligand, in high enantiomeric excess (>99%) is reported. The synthesis features an ester-derived titanium enolate based highly stereoselective anti-aldol reaction as the key step.
Key Words
antiviral agents - asymmetric synthesis - chiral auxiliary - aldol reactions - fused-ring systems
- 1
.
2004 Report on the Global HIV/AIDS Epidemic
4th Global Report;
New York, USA:
2004.
- 2a
Flexner C. N. Engl. J. Med. 1998, 338: 1281 - 2b
Cihlar T.Bischofberger N. Annu. Rep. Med. Chem. 2000, 35: 1777 - 3a
Grabar S.Pradier C.Le Corfec E.Lancer R.Allavena C.Bentata M.Berlureau P.Dupont C.Fabbro-Peray P.Poizot-Martin I.Cosatagliola D. AIDS 2000, 14: 141 - 3b
Richman DD. Nature 2001, 410: 995 - 4a
Ghosh AK.Shin DW.Swanson L.Krishnan K.Cho H.Hussain KA.Walters DE.Holland L.Buthod J. Farmaco 2001, 56: 29 - 4b
Ghosh AK.Kincaid JF.Cho W.Walters DE.Krishnan K.Hussain KA.Koo Y.Cho H.Rudall C.Holland L.Buthod J. Bioorg. Med. Chem. Lett. 1998, 8: 687 - 4c
Koh Y.Nakata H.Maeda K.Ogata H.Bilcer G.Devasamudram T.Kincaid JF.Boross P.Wang Y.-F.Tie Y.Volarath P.Gaddis L.Harrison RW.Weber IT.Ghosh AK.Mitsuya H. Antimicrob. Agents Chemother. 2003, 47: 3123 - 4d
Yoshimura K.Kato R.Kavlick MF.Nguyen A.Maroun V.Maeda K.Hussain KA.Ghosh AK.Gulnik SV.Erickson JW.Mitsuya H. J. Virol. 2002, 76: 1349 - 5a
De Meyer S.Peeters M. Conference on Retroviruses and Opportunistic Infections (11th CROI), Feb 8-11 San Francisco, USA: 2004. Abstracts 533 and 620 - 5b
Surleraux DLNG.Tahri A.Verschueren WG.Pille GME.de Kock HA.Jonckers THM.Peeters A.De Meyer S.Azijn H.Pauwels R.de Bethune M.-P.King NM.Prabu-Jeyabalan M.Schiffer CA.Wigerinck PBTP. J. Med. Chem. 2005, 48: 1813 - 5c
Sorbera LA.Castaner J.Bayes M. Drugs Future 2005, 30: 441 - 7
Miller JF.Andrews CW.Brieger M.Furfine ES.Hale MR.Hanlon MH.Hazen RJ.Kaldor I.McLean EW.Reynolds D.Sammond DM.Spaltenstein A.Tung R.Turner EM.Xu RX.Sherrill RG. Bioorg. Med. Chem. Lett. 2006, 16: 1788 - 8a
Ghosh AK.Kincaid JF.Walters DE.Chen Y.Chaudhuri NC.Thompson WJ.Culberson C.Fitzgerald PMD.Lee HY.McKee SP.Munson PM.Duong TT.Darke PL.Zugay JA.Schleif WA.Axel MG.Lin J.Huff JR. J. Med. Chem. 1996, 39: 3278 - 8b
Ghosh AK.Chen Y. Tetrahedron Lett. 1995, 36: 505 - 8c
Ghosh AK.Leshchenko S.Noetzel M. J. Org. Chem. 2004, 69: 7822 - 9
Quaedflieg PJLM.Kesteleyn BRR.Wigerinck PBTP.Goyvaerts NMF.Vijn RJ.Liebregts CSM.Kooistra JHMH.Cusan C. Org. Lett. 2005, 7: 5917 - For recent ester enolate-based anti-aldol procedures, see:
- 10a
Ghosh AK.Kim J. Org. Lett. 2003, 5: 1063 - 10b
Ghosh AK.Fidanze S. Org. Lett. 2000, 2: 2405 - 10c
Ghosh AK.Onishi M. J. Am. Chem. Soc. 1996, 118: 2527 - 11a
Ghosh AK.Bischoff A.Cappiello J. Eur. J. Org. Chem. 2003, 821 - 11b
Ghosh AK.Bischoff A.Cappiello JJ. Org. Lett. 2001, 3: 2677 - 13
Dale JA.Dull DL.Mosher HS. J. Org. Chem. 1969, 34: 2543
References
On June 23, 2006, the FDA approved a new HIV treatment for patients who do not respond to existing drugs; see: www.fda.gov/bbs/topics/NEWS/2006/NEW01395.html.
12The Mosher ester was formed by the reaction of Mosher acid and alcohol 3 with EDCI in the presence of DMAP. The 19F NMR analysis of the Mosher ester13 revealed an enantiomeric purity of >99%.